Scope 3 Emissions: A Strategic Imperative for Pharma Companies

Insight Exchange by L.E.K. Consulting

In this episode of “Insight Exchange,” we explore the crucial role of Scope 3 emissions reduction in the pharmaceutical industry. Listen to L.E.K. Consulting experts Verena Ahnert and Max Cambras, who share their insights on the significance of Scope 3 emissions, the current state of commitments in pharma and how emissions reduction is both a strategic consideration and mutually beneficial to both pharma and the environment.

Key points/topics covered:

• Explanation of Scope 3 emissions and their importance in pharma

• The current state of Scope 3 commitments in the pharmaceutical industry

• Key drivers of Scope 3 emissions in pharma

• The strategic co-benefits of Scope 3 emissions reduction in the pharmaceutical industry

• The path to achieving strategic co-benefits through emissions reduction in pharma

Tune in for a deep dive into a pressing environmental issue that’s reshaping the pharma industry’s strategies and operations.

Interested in learning more? Read our Special Report, Scope 3 Emissions: A Strategic Imperative for Pharma Companies.

Connect with our experts on LinkedIn:
Verena Ahnert, Partner, L.E.K. Consulting: https://www.linkedin.com/in/verena-ahnert-7a449a2/
Max Cambras, Managing Director, L.E.K. Consulting: https://www.linkedin.com/in/max-cambras-08348411/

Visit L.E.K. Consulting at https://www.lek.com/